Rezultati pretraživanja
  1. prije 8 sati
  2. 5. velj

    Intercept Pharmaceuticals Inc Receives Average Rating of “Buy” from Analysts

  3. 5. velj

    ICPT has a beautiful bottom curl to it on the daily chart. Watch for continuation tomorrow for a push back towards $100 than $107.50

  4. 4. velj

    up over 300 bucks in 2 days, still can't believe it lol makes previous moves in and others look like a joke

  5. 4. velj

    had to sell all my except for the 1 share I have framed in my basement...now it will go back to $400

  6. 4. velj
  7. 3. velj

    - Monthly performance of the algo based option alerts posted for ICPT

  8. 3. velj

    - Last six months, 13 option alerts peaked above 100% after they were triggered by the algo

  9. 3. velj

    Peak profit for the last 6 expired option alerts for 105.56 % | -9.80 % | 204.35 % | 6.67 % | 200.45 % | 0.00 % |

  10. 1. velj

    Intercept Pharmaceuticals Earns “Buy” Rating from Wedbush

  11. 1. velj

    stock was down -1.54 %. Turned Positive 0.73 % | (Red to green move) See other red to green mo ves using

  12. 31. sij

    Short sale vol (not short interest) for on 2020-01-30 is 31%. 28% 80% 74% 53%

  13. 29. sij
    Prikaži ovu nit
  14. 29. sij

    Insider Selling: Intercept Pharmaceuticals Inc EVP Sells 723 Shares of Stock

  15. 28. sij

    (+31% AH) Hepion announced positive findings that CRV431 prevented experimentally induced liver fibrosis to a greater extent than obeticholic acid (FXR), elafibranor (PPARα/δ), resmetirom (THR-β), and Aramchol (SCD1).

  16. 26. sij

    Any hope for in 2020? Which will be best clinical results to come?

  17. 23. sij

    Genfit -8% ce 23/01(volumes significatifs): je n'ai pas vu de News de concurrents ou d'update de brokers. Je remarque que les sociétés NASH en P3 et font l'objet d'attaques en 2020. La seule qui échappait à cette vague baissière était cc

  18. JEFF thoughts on M&A, outlook on macro/micro " still large interest in M&A " (6:27) (10:15) (15:25) (19:03) (22:09) (25:15) (27) (29) (30) (31) (32) (33)

  19. 14. sij

    This is a fascinating insight into the commercial view from in First, will biopsy be required? They think... No. Second, what will the price be? Non-committal, but "specialty pricing" so high - a brief thread on use of OCA and the $$ involved 1/n

    Prikaži ovu nit
  20. On the cusp of FDA approval for its NASH drug, CEO talks payers, pruritis, and price

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.